查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1573979

郁血性心臟衰竭：按类型、诊断、治疗和最终用户划分 - 全球预测 2025-2030

Congestive Heart Failure Market by Type (Left-Sided Heart Failure, Right-Sided Heart Failure), Diagnosis (Blood Tests, Electrocardiogram, Imaging Tests), Treatment, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年郁血性心臟衰竭市值为64.3亿美元，预计2024年将达到67.9亿美元，复合年增长率为7.31%，到2030年将达到105.4亿美元。

郁血性心臟衰竭（CHF）是一种严重的疾病，其特征是心臟无法有效泵血，影响各种身体功能。 CHF 的范围和定义包括冠状动脉疾病、高血压和糖尿病等疾病导致的心臟生理性衰竭。随着这些疾病的日益流行，对有效管理和治疗解决方案的需求变得至关重要。 CHF 的治疗包括药物介入、生活型态改变、外科手术以及心律调节器和辅助人工心臟等新技术。就最终用途而言，市场范围涵盖医院、心臟中心、门诊手术中心和居家照护机构。 CHF 市场的主要成长动力包括人口老化、医疗保健意识的提高以及先进医疗技术的采用。人工智慧和远端医疗的最新进展为加强病患监测和个人化治疗计划提供了重要机会。利用这些机会的建议包括投资数位健康解决方案以及与高科技公司合作开发创新产品。然而，由于高昂的治疗成本、严格的法律规范以及医疗保健系统报销的复杂性，市场成长面临限制。应对这些挑战需要对具有成本效益的技术进行策略性投资，并采取强有力的合规措施来应对监管环境。创新和研究的最佳领域包括开发针对慢性心臟衰竭根本原因的新型药物疗法以及用于早期检测的非侵入性诊断工具。基因治疗和再生医学也具有巨大潜力。对 CHF 市场的洞察揭示了由技术创新和以患者为中心的护理需求驱动的动态环境。为了发展您的业务，请专注于协作研究，加强您现有的产品系列，并扩大您的地理覆盖范围，以便在这个不断发展的市场中获得竞争优势。

主要市场统计
基准年[2023] 64.3亿美元
预测年份 [2024] 67.9亿美元
预测年份 [2030] 105.4亿美元
复合年增长率（%） 7.31%

市场动态：揭示快速发展的郁血性心臟衰竭市场的关键市场洞察

供需的动态交互作用正在改变郁血性心臟衰竭市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对微创手术和心臟衰竭治疗程序的需求不断增长
    • 扩大新兴市场的医疗服务范围并改善诊断设施
    • 製药公司之间在药物开发的联盟与合作增加
    • 提高病患对早期诊断和管理方案的认识和教育倡议
  • 市场限制因素
    • 具有郁血性心臟衰竭专业知识的专业医疗保健提供者的数量有限
    • 高合併症使郁血性的治疗和结果变得复杂，降低了市场有效性
  • 市场机会
    • 将人工智慧和机器学习整合到郁血性心臟衰竭和治疗中
    • 充血心臟衰竭郁血性微创外科技术治疗进展
    • 利用患者特定资料制定个人化郁血性心臟衰竭计划
  • 市场挑战
    • 加强监管，影响郁血性心臟衰竭的核准和分配
    • 新生物技术和郁血性心臟衰竭疗法的竞争加剧

波特五力：驾驭郁血性心臟衰竭的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解郁血性心臟衰竭的外部影响

外部宏观环境因素在塑造郁血性心臟衰竭的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解郁血性心臟衰竭的竞争格局

对郁血性心臟衰竭的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵郁血性心臟衰竭供应商的绩效评估

FPNV定位矩阵是评估郁血性心臟衰竭供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了郁血性心臟衰竭的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对郁血性心臟衰竭市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对微创手术和心臟衰竭治疗程序的需求增加
      • 扩大新兴市场的医疗服务范围并改善诊断设施
      • 加强製药公司在药物开发方面的联盟与合作
      • 扩大患者对早期诊断和治疗选择的认识和教育工作
    • 抑制因素
      • 具有郁血性心臟衰竭专业知识的专业医疗保健提供者的数量有限
      • 合併症的高盛行率使郁血性心臟衰竭的治疗和结果变得复杂，从而降低了市场有效性。
    • 机会
      • 将人工智慧和机器学习整合到郁血性心臟衰竭和治疗中
      • 充血心臟衰竭郁血性微创外科技术治疗进展
      • 利用患者特定资料制定个人化郁血性心臟衰竭计划
    • 任务
      • 加强监管会影响郁血性心臟衰竭的核准和分配
      • 新兴生物技术和替代治疗方法加剧了郁血性的竞争
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章郁血性心臟衰竭：依类型

  • 左心臟衰竭
    • 舒张性心衰竭
    • 收缩性心臟衰竭
  • 右心臟衰竭

第七章郁血性心臟衰竭市场

  • 验血
    • 脑钠肽测试
    • 电解质水平测试
    • NT-proBNP 测试
  • 心电图
  • 影像检查
    • 电脑断层扫描
    • 心臟超音波图
    • MRI
  • 压力测试
    • 运动压力测试
    • 核子压力测试

第八章郁血性心臟衰竭市场

  • 医疗设备
    • 心臟再同步治疗装置
    • 植入式心臟整流去颤器
    • 心律调节器
  • 药品
    • ACE抑制剂
    • 醛固酮拮抗剂
    • β受体阻断剂
    • 利尿剂
    • 血管扩张剂
  • 外科手术
    • 冠状动脉绕道术
    • 心臟瓣膜修復或更换

第九章郁血性心臟衰竭：依最终用户分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第10章美洲郁血性心臟衰竭

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太郁血性心臟衰竭

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲郁血性心臟衰竭市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C04DC

The Congestive Heart Failure Market was valued at USD 6.43 billion in 2023, expected to reach USD 6.79 billion in 2024, and is projected to grow at a CAGR of 7.31%, to USD 10.54 billion by 2030.

Congestive Heart Failure (CHF) is a significant medical condition characterized by the heart's inability to pump blood effectively, impacting various bodily functions. The scope and definition of CHF encompass the physiological inadequacies of the heart, often due to conditions such as coronary artery disease, hypertension, or diabetes. With the increasing prevalence of these conditions, the necessity for effective management and treatment solutions is paramount. The application of treatments for CHF includes pharmacological interventions, lifestyle modifications, surgical procedures, and emerging technologies like pacemakers and ventricular assist devices. In terms of end-use, the market scope spans hospitals, cardiac centers, ambulatory surgical centers, and home care settings. Key growth drivers in the CHF market include an aging population, rising healthcare awareness, and the adoption of advanced healthcare technologies. Recent advancements in AI and telemedicine offer substantial opportunities for enhancing patient monitoring and personalized treatment plans. Recommendations to capitalize on these opportunities include investing in digital health solutions and forming partnerships with tech companies for innovative product development. Market growth, however, faces limitations due to high treatment costs, stringent regulatory frameworks, and the complex nature of healthcare system reimbursements. Addressing these challenges requires strategic investment in cost-effective technologies and navigating regulatory landscapes with robust compliance measures. Best areas for innovation and research include the development of novel drug therapies targeting the underlying causes of CHF, and non-invasive diagnostic tools for early detection. Exploring gene therapy and regenerative medicine also presents immense potential. Insight into the CHF market reveals a dynamic environment driven by technological innovation and patient-centric care demands. For business growth, a focus on collaborative research, enhancing existing product portfolios, and expanding geographic reach can provide competitive advantages in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.43 billion
Estimated Year [2024] USD 6.79 billion
Forecast Year [2030] USD 10.54 billion
CAGR (%) 7.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Congestive Heart Failure Market

The Congestive Heart Failure Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for minimally invasive surgeries and heart failure management procedures
    • Expanding healthcare access and improving diagnostic facilities in emerging markets
    • Increasing partnerships and collaborations among pharmaceutical companies for drug development
    • Growing patient awareness and education initiatives regarding early diagnosis and management options
  • Market Restraints
    • Limited availability of specialized healthcare providers with expertise in congestive heart failure management
    • High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
  • Market Opportunities
    • Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
    • Advancement of minimally invasive surgical techniques for congestive heart failure treatment
    • Utilization of patient-specific data in personalized congestive heart failure treatment plans
  • Market Challenges
    • Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
    • Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure

Porter's Five Forces: A Strategic Tool for Navigating the Congestive Heart Failure Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Congestive Heart Failure Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Congestive Heart Failure Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Congestive Heart Failure Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Congestive Heart Failure Market

A detailed market share analysis in the Congestive Heart Failure Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Congestive Heart Failure Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Congestive Heart Failure Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Congestive Heart Failure Market

A strategic analysis of the Congestive Heart Failure Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Congestive Heart Failure Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer AG, Biotronik, Boston Scientific Corporation, Bristol-Myers Squibb Company, CVRx, Inc., Eli Lilly and Company, GlaxoSmithKline plc, HeartWare International Inc., Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., ResMed, Sanofi S.A., Teleflex Incorporated, and Thoratec Corporation.

Market Segmentation & Coverage

This research report categorizes the Congestive Heart Failure Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Left-Sided Heart Failure and Right-Sided Heart Failure. The Left-Sided Heart Failure is further studied across Diastolic Heart Failure and Systolic Heart Failure.
  • Based on Diagnosis, market is studied across Blood Tests, Electrocardiogram, Imaging Tests, and Stress Tests. The Blood Tests is further studied across BNP Test, Electrolyte Level Test, and NT-proBNP Test. The Imaging Tests is further studied across CT Scan, Echocardiogram, and MRI. The Stress Tests is further studied across Exercise Stress Test and Nuclear Stress Test.
  • Based on Treatment, market is studied across Medical Devices, Medications, and Surgical Procedures. The Medical Devices is further studied across Cardiac Resynchronization Therapy Devices, Implantable Cardioverter Defibrillators, and Pacemakers. The Medications is further studied across ACE Inhibitors, Aldosterone Antagonists, Beta Blockers, Diuretics, and Vasodilators. The Surgical Procedures is further studied across Coronary Bypass Surgery and Heart Valve Repair or Replacement.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for minimally invasive surgeries and heart failure management procedures
      • 5.1.1.2. Expanding healthcare access and improving diagnostic facilities in emerging markets
      • 5.1.1.3. Increasing partnerships and collaborations among pharmaceutical companies for drug development
      • 5.1.1.4. Growing patient awareness and education initiatives regarding early diagnosis and management options
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of specialized healthcare providers with expertise in congestive heart failure management
      • 5.1.2.2. High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
      • 5.1.3.2. Advancement of minimally invasive surgical techniques for congestive heart failure treatment
      • 5.1.3.3. Utilization of patient-specific data in personalized congestive heart failure treatment plans
    • 5.1.4. Challenges
      • 5.1.4.1. Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
      • 5.1.4.2. Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Congestive Heart Failure Market, by Type

  • 6.1. Introduction
  • 6.2. Left-Sided Heart Failure
    • 6.2.1. Diastolic Heart Failure
    • 6.2.2. Systolic Heart Failure
  • 6.3. Right-Sided Heart Failure

7. Congestive Heart Failure Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
    • 7.2.1. BNP Test
    • 7.2.2. Electrolyte Level Test
    • 7.2.3. NT-proBNP Test
  • 7.3. Electrocardiogram
  • 7.4. Imaging Tests
    • 7.4.1. CT Scan
    • 7.4.2. Echocardiogram
    • 7.4.3. MRI
  • 7.5. Stress Tests
    • 7.5.1. Exercise Stress Test
    • 7.5.2. Nuclear Stress Test

8. Congestive Heart Failure Market, by Treatment

  • 8.1. Introduction
  • 8.2. Medical Devices
    • 8.2.1. Cardiac Resynchronization Therapy Devices
    • 8.2.2. Implantable Cardioverter Defibrillators
    • 8.2.3. Pacemakers
  • 8.3. Medications
    • 8.3.1. ACE Inhibitors
    • 8.3.2. Aldosterone Antagonists
    • 8.3.3. Beta Blockers
    • 8.3.4. Diuretics
    • 8.3.5. Vasodilators
  • 8.4. Surgical Procedures
    • 8.4.1. Coronary Bypass Surgery
    • 8.4.2. Heart Valve Repair or Replacement

9. Congestive Heart Failure Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Congestive Heart Failure Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Congestive Heart Failure Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Congestive Heart Failure Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CONGESTIVE HEART FAILURE MARKET RESEARCH PROCESS
  • FIGURE 2. CONGESTIVE HEART FAILURE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONGESTIVE HEART FAILURE MARKET DYNAMICS
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BNP TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROLYTE LEVEL TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NT-PROBNP TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY EXERCISE STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NUCLEAR STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR OR REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 322. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDU